AD-LIB.IO
Ad-Lib.io , the next-generation Creative Management Platform for marketers at the world’s largest brands, today announced that it has been certified as a Google Marketing Platform (GMP) Partner in Spain, bringing Ad-Lib.io its sixth creative certification as it continues to extend its footprint across the globe.
The GMP Creative Certification in Spain affirms that Ad-Lib.io has demonstrated the ability to work within Google’s best practices and technology, and reinforces that its next-generation Creative Management Platform upholds high standards of service for creative design and process management. The certification reaffirms Ad-Lib.io’s successful client track record and its expertise across key capabilities including coding, asset delivery, and client services. The certification gives Ad-Lib.io , early access to product releases and announcements, and to a variety of other Google program resources.
“As the advertising industry emerges from a difficult year, advertisers are pushed to make their creative workflow more efficient while ensuring their ads stand out and perform well,” said Adit Abhyankar, CEO of Ad-Lib.io. “As a Google Marketing Platform Partner certified on the Creative tools, Ad-Lib.io offers advertisers in Spain on Google’s tech stack, the ability to easily and quickly build and activate content at scale, across formats and channels. Ad-Lib.io has been a trusted Google Partner since our founding in 2017 and we will continue to lead the way for advertisers that seek to produce and optimize relevant creative at scale.”
“As Google and its customers continue to find new ways to work together, partners like Ad-Lib.io are an important part of our ecosystem as they got certified.” according to Jose Maria Perez Sastre, Partnerships Manager at Google. “We are pleased that Ad-Lib.io continues to grow its presence and customers in Spain. We have seen great success already working together on clients in the region and we look forward to the continuing partnership in Spain and in other markets around the globe.”
This milestone strengthens Ad-Lib.io’s capability for customers working with the Google Marketing Platform in Spain and globally, as marketers seek solution providers that operate in the markets they serve. One partner with multi-region certifications, Ad-Lib.io is also a GMP Creative Partner in the United Kingdom, the United States, Dubai, Australia and Singapore.
“I'm very excited by the launch of another Google-certified market in Spain!” said Oli Marlow Thomas, founder of Ad-Lib.io. “This accompanies the awesome news that Ad-Lib.io DE is now up and running with former Googler Felix Derkum leading the charge. Ad-Lib.io is pushing into all parts of Europe.”
For more information about Ad-Lib.io, please visit: https://www.ad-lib.io/ .
About Ad-Lib.io
Ad-Lib.io provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-Lib.io’s customers which include 10 of the top 30 global brands. The venture-backed company -- recognized as a 2021 Start Up of the Year by Campaign Magazine -- was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution. Ad-Lib.io is headquartered in London, UK with offices in North America, Asia, Australia, Europe and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
